Kameda Kazuaki, Kimura Shun-Ichi, Akahoshi Yu, Nakano Hirofumi, Harada Naonori, Ugai Tomotaka, Wada Hidenori, Yamasaki Ryoko, Ishihara Yuko, Kawamura Koji, Sakamoto Kana, Ashizawa Masahiro, Sato Miki, Terasako-Saito Kiriko, Nakasone Hideki, Kikuchi Misato, Yamazaki Rie, Kanda Junya, Kako Shinichi, Tanihara Aki, Nishida Junji, Kanda Yoshinobu
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Biol Blood Marrow Transplant. 2016 Feb;22(2):371-377. doi: 10.1016/j.bbmt.2015.09.019. Epub 2015 Sep 28.
Bloodstream infections (BSI) are still important complications after allogeneic hematopoietic stem cell transplantation (allo-SCT). Patients who are receiving corticosteroid therapy can develop BSI without fever. The utility of surveillance blood cultures in these situations is controversial. We retrospectively analyzed 74 patients who received a corticosteroid consisting of ≥.5 mg/kg prednisolone or equivalent after allo-SCT. In principle, we performed surveillance blood culture weekly for these patients. Sixteen patients (21.6%) developed definite BSI. In a multivariate analysis, a myeloablative conditioning regimen, high-risk disease status at allo-SCT, and the presence of a central venous catheter at the initiation of corticosteroid therapy were identified as independent significant risk factors for the development of definite BSI. At the first definite BSI episode, 7 patients (46.7%) were afebrile and diagnosed by surveillance blood culture. However, 6 of these 7 afebrile patients showed various signs that could be attributed to infection at the time of positive blood culture. In conclusion, patients receiving corticosteroid therapy after allo-SCT frequently develop afebrile BSI. Although surveillance blood culture might be beneficial in these situations, it also seems important to not miss the signs of BSI, even when patients are afebrile.
血流感染(BSI)仍是异基因造血干细胞移植(allo-SCT)后重要的并发症。接受皮质类固醇治疗的患者可能在无发热情况下发生BSI。在这些情况下,监测血培养的作用存在争议。我们回顾性分析了74例allo-SCT后接受≥0.5mg/kg泼尼松龙或等效皮质类固醇治疗的患者。原则上,我们每周为这些患者进行监测血培养。16例患者(21.6%)发生明确的BSI。多因素分析显示,清髓性预处理方案、allo-SCT时的高危疾病状态以及开始皮质类固醇治疗时存在中心静脉导管是明确BSI发生的独立显著危险因素。在首次明确的BSI发作时,7例患者(46.7%)无发热,通过监测血培养确诊。然而,这7例无发热患者中有6例在血培养阳性时出现了各种可归因于感染的体征。总之,allo-SCT后接受皮质类固醇治疗的患者常发生无发热的BSI。虽然在这些情况下监测血培养可能有益,但即使患者无发热,也不能漏诊BSI的体征,这似乎也很重要。